These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 27244255

  • 1. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Wang J, Hu J, Jin Z, Wan H.
    Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
    Liu Z, Li Y, Lv C, Wang L, Song H.
    Biochem Biophys Res Commun; 2016 Sep 16; 478(2):893-9. PubMed ID: 27520370
    [Abstract] [Full Text] [Related]

  • 5. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M.
    Oncotarget; 2015 Oct 13; 6(31):30487-99. PubMed ID: 26431162
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A, Buckle AM, Hiwarkar P, Syed F.
    PLoS One; 2015 Oct 13; 10(4):e0123016. PubMed ID: 25849484
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.
    Blood; 1996 Oct 15; 88(8):3091-100. PubMed ID: 8874208
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C, Mulholland T, Zagnoni M, Dalby M, Berry C, Wheadon H.
    Cell Commun Signal; 2023 Nov 29; 21(1):342. PubMed ID: 38031192
    [Abstract] [Full Text] [Related]

  • 12. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
    Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M.
    Sci Transl Med; 2016 Sep 07; 8(355):355ra117. PubMed ID: 27605552
    [Abstract] [Full Text] [Related]

  • 13. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X, Tu H, Yang Y, Jiang X, Hu X, Luo Q, Li J.
    J Biol Chem; 2019 Aug 09; 294(32):12167-12179. PubMed ID: 31235520
    [Abstract] [Full Text] [Related]

  • 14. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP, Fang BJ, Wei XD, Zheng S.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec 09; 13(6):1004-9. PubMed ID: 16403268
    [Abstract] [Full Text] [Related]

  • 15. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
    Tan Z, Peng A, Xu J, Ouyang M.
    BMC Anesthesiol; 2017 Sep 29; 17(1):132. PubMed ID: 28962554
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L, Yu J, Chen R, Liu Y, Lou L, Wu Y, Huang L, Fan Y, Gao P, Huang M, Wu Y, Chen Y, Xu J.
    Clin Cancer Res; 2015 Feb 15; 21(4):833-43. PubMed ID: 25501124
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.
    Am J Hematol; 2012 Nov 15; 87(11):E125-8. PubMed ID: 23044928
    [Abstract] [Full Text] [Related]

  • 20. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
    Holtz MS, Forman SJ, Bhatia R.
    Leukemia; 2005 Jun 15; 19(6):1034-41. PubMed ID: 15815728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.